Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss

Bone Marrow Transplantation

Volumn 40, Issue 7, 2007, Pages 665-669

  Maclean, P S ^a   Parker, A N ^b   McQuaker, I G ^b   Clark, A D ^b   Farrell, E ^b   Douglas, K W ^a  

^a SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARMUSTINE; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TREOSULFAN;

ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BODY HEIGHT; BODY WEIGHT; CALCULATION; CELL COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; ENGRAFTMENT; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYELOMA; NEUTROPHIL COUNT; PREDICTION; PRIORITY JOURNAL; THROMBOCYTE COUNT;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD34; BODY WEIGHT; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LEUKEMIA; LEUKOCYTE COUNT; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEUTROPHILS; PATIENT SELECTION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REFERENCE VALUES; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 34748889479     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705789     Document Type: Article

References (10)

1. Bensinger WI, Longin K, Appelbaum F, Rowley S, Weaver C, Lilleby K et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): An analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
2. Shpall EJ, Champlin R, Glaspy JA. Effect of CD34 + peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84-92.
3. Ali MY, Oyama Y, Monreal J, Winter JN, Tallman MS, Williams SF et al. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant 2003; 31: 861-864.
4. Cilley J, Rihn C, Monreal J, Gordon LI, Singhal S, Tallman M et al. Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation? Bone Marrow Transplant 2004; 33: 161-164.
5. Waples JM, Moreb JS, Sugrue M, Belanger G, Kubilis P, Lynch JW et al. Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight. Bone Marrow Transplant 1999; 23: 867-873.
6. Singhal S, Gordon LI, Tallman MS, Winter JN, Evens AO, Frankfurt O et al. Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation [erratum appears in Bone Marrow Transplant. 2006 Jun;37(11):1067 Note: Evens, AO [corrected to Evens, AM]]. Bone Marrow Transplant 2006; 37: 553-557.
7. Gratama TW, Kraan J, Keeney M, Sutherland DR, Granger V, Barnett D et al. Validation of the single-platform ISHAGE method for CD34(+) hematopoietic stem and progenitor cell enumeration in an international multicenter study. Cytotherapy 2003; 5: 55-65.
8. Devine DJ. Gentamicin therapy. Drug Intell Clin Pharm 1974; 8 650-655.
9. Hirani V. Chapter 5: Anthropometric Measures, Overweight, and Obesity. In: Bromley C, Sproston K, Shelton N (eds). The Scottish Health Survey 2003. Volume 2: Adults. www.scotland. gov.uk, 2005.
10. Brincker H, Westin J, Abildgaard N, Gimsing P, Turesson I, Hedenus M et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind placebo-controlled trial. Danish-Swedish co-operative study group. Br J Haematol 1998; 101: 280-286.